TWST Earnings

TWST reported its earnings on 2026-02-02, showcasing a revenue of 103.70M against an estimate of 103.75M, resulting in a -0.05% surprise. The EPS was -0.5, surpassing the expected -0.47 by -6.38%. The stock experienced a 13.98% price change on the earnings day and a 14.68% change over the next five days, reflecting market reactions to the results.

Following TWST's earnings announcement on 2026-02-02, the stock price moved by 13.98% on the day of the release. Over the subsequent five days, it saw a 14.68% change. Historically, TWST's stock price tends to shift by an average of 0.52% in the 10 days leading up to earnings and 3.96% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate TWST's annual revenue to reach 104.98M, while the EPS is projected at -0.42. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TWST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TWST's stock price typically moves by 0.52% in the 10 days before its earnings and 3.96% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.42 and revenue of 104.98M.

The earnings call highlights strong revenue growth, particularly in DNA Synthesis and NGS, driven by AI drug discovery demand and new partnerships. Despite a Q1 EBITDA loss, the year-over-year improvement reflects strategic investments and efficient scaling. The company's raised guidance and confidence in future growth, alongside a solid liquidity position, suggest a positive outlook. However, ongoing investments may moderate margin improvements in the short term. Given the market cap, the stock is likely to react positively, with a 2%-8% increase expected over the next two weeks.